mRNA

SM-102 is the only ionizable amino cationic lipid currently clinically approved for RNA therapeutics and can be used to synthesize lipid nanoparticles (LNPs). It shows potential in the development of LNPs for the delivery of mRNA-based vaccines.

CD19 car mRNA-LNP, a lipid nanoparticle (LNP) encapsulating CD19 car mRNA, is instrumental in assessing RNA delivery, translation efficacy, and cell viability among other applications. This compound is pivotal for chimeric antigen receptor T cell immunotherapy (CAR-CD19), leveraging the CD19 molecule - a critical membrane antigen expressed by B cells (i.e., leukocyte differentiation antigen) that plays a significant role in their proliferation, differentiation, activation, and antibody production, as well as enhancing BCR signal transduction [1] [2].

COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) formulated with the novel coronavirus pneumonia spike protein, positioned on the membrane surface. It is designed for applications such as RNA delivery, translation efficiency, and cell viability assessment. This spike protein facilitates the COVID-19 virus's entry into host cells by binding to cell membrane receptors and enabling membrane fusion, making it a critical focal point for host neutralizing antibodies and vaccine development [1].

mRNA-Encapsulating Lipid Excipient 1 (Compound 2), a thiocarbamate-based ionizable lipid, serves as an excipient in the formulation of mRNA-encapsulating lipid nanoparticles [1].

Firefly luciferase mRNA-LNP is a lipid nanoparticle (LNP) comprising Firefly luciferase mRNA, designed for assays involving RNA delivery, translation efficiency, and cell viability. It serves as a bioluminescent reporter gene for studies on gene regulation and function. Once inside cells, Firefly luciferase mRNA produces firefly luciferase protein, making it suitable for promoter activity assays or dual-luciferase complementation experiments. Common luciferases include Firefly luciferase and Renilla luciferase.

C12-200 is a benchmark ionizable cationic lipidoid along with helper lipids and can be used in the delivery of mRNA.

ALC-0315 is an ionizable amino lipid that has been used in combination with other lipids to form lipid nanoparticles. Lipid-Nanoparticles have been used in the research of mRNA COVID-19 vaccine

DODAP is an ionic cationic lipid with low cytotoxicity and high transfection efficiency that can be used to synthesize liposomes and encapsulate biologically active molecules such as mRNA, siRNA and plasmid DNA.

Lipid 5, an amino lipid compound, demonstrates proficient mRNA delivery in rodent and primate models, with favorable pharmacokinetics and minimal toxicity.

BAMEAO16B is a lipid nanoparticle that incorporates disulfide bonds for efficient delivery of Cas9 mRNA and sgRNA into cells. In the intracellular environment, BAMEAO16B responds to reduction by releasing RNA, facilitating genome editing. This compound is valuable for gene editing research purposes.

24:0 Lyso PC, a lysophospholipid (LyP), has potential applications in mRNA drug delivery.

7-Methyl-diguanosine triphosphate (m7Gp3G) is a cap analog that incorporates into mRNA, significantly influencing translation and mRNA degradation in mammalian cells.

N1-Methylpseudouridine-5'-triphosphate trisodium is a modified NTP that can be incorporated into messenger RNA (mRNA) by enzymes like T7 RNA polymerase.

Lipid M (pKa: 6.75) is a potential carrier for mRNA vaccines, offering enhanced immune responses and increased tolerability [1].

CKK-E12 is a selective ionizable lipid that often binds to other lipids to form carrier mRNA lipid nanoparticles.CKK-E12 is used in the study of RNA-related diseases.

Pseudouridine-5'-triphosphate (Pseudo-UTP) is widely known for its role in polymerase-mediated RNA synthesis, frequently surpassing uridine in unmodified mRNAs due to improved nuclease stability, immunogenicity, and translational properties.

18:0 DAP can be utilized in the formulation of lipid nanoparticles (LNPs) that encapsulate mRNA within their core [1].

FTT5 is an ionizable lipidsfor efficient delivery of long mRNAs in vivo.

OF-02, an alkenyl amino alcohol (AAA) ionizable lipid, demonstrates high potency for in vivo mRNA delivery.

N1,N3,N5-Tris(4-dodecylhexadecyl)benzene-1,3,5-tricarboxamide is an analogue of TT3 . TT3 is an ionizable lipid-like materials for mRNA and CRISPR Cas9 delivery [1] [2] .

3'Ome-m7GpppAmpG ammonium, a trinucleotide Cap analogue with a locked nucleic acid (LNA) component, demonstrates substantial translational efficiency. It emerges as a promising tool in molecular biology, applicable in mRNA vaccines and transfection processes including protein production, gene therapy, and anti-cancer immunization [1].

M7Gpppm6AmpG ammonium, a trinucleotide mRNA 5' cap analog, facilitates in vitro RNA synthesis [1].

TCL053, an ionizable lipid carrier, efficiently facilitates the introduction of active components, particularly nucleic acids, into cells. In combination with Dipalmitoylphosphatidylcholine (DPPC), Polyethylene glycol dimyristoyl glycerol (PEG-DMG), and cholesterol, TCL053 composes a lipid nanoparticle (LNP) system capable of delivering Cas9 mRNA and sgRNA into skeletal muscle [1] [2].

TT3 is an ionizable lipid-like material used for the delivery of mRNA and CRISPR Cas9 [1] [2].